Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(reslizumab)
187 results
  • Monoclonal antibodies in severe asthma: is it worth it? [Meta-Analysis]
  • EOExpert Opin Drug Metab Toxicol 2019; 15(6):517-520
  • Calzetta L, Matera MG, Rogliani P
  • CONCLUSIONS: Further extensive meta-analyses are needed to identify the factors influencing the efficacy profile of mAbs in severe asthma. This may also permit to identify the profile of patients that are specifically responsive to either anti-IgE, anti-IL-4Rα, anti-IL-5, or anti-IL-5Rα mAbs.
  • New Targeted Therapies for Uncontrolled Asthma. [Review]
  • JAJ Allergy Clin Immunol Pract 2019 May - Jun; 7(5):1394-1403
  • Corren J
  • Mechanistic studies have improved our understanding of molecular and cellular components involved in asthma and our ability to treat severe patients. An mAb directed against IgE (omalizumab) has beco…
New Search Next